Key Highlights
- An interim analysis of the 2,116-patient VOICE trial, announced June 30, 2026, met prespecified stopping criteria, prompting the monitoring committee to recommend halting the study early.
- The composite endpoint favored Vafseo over an ESA with a win odds of 1.16, driven by a significant cut in hospitalizations; mortality was not significantly different between arms.
- Vafseo's Transitional Drug Add-on Payment Adjustment, the extra Medicare payment cushioning its launch, expires around year-end 2026, two years after its January 2025 start.
- Auryxia, Akebia's legacy phosphate binder, lost patent exclusivity in March 2025 and faces expanding generic competition, pressuring the revenue base funding most operations.
Akebia (NASDAQ:AKBA) Therapeutics and U.S. Renal Care stopped the VOICE trial early in June 2026 after an interim look showed Vafseo cut hospitalizations significantly versus a standard anemia drug, a result the companies called overwhelming. Layered on a still-loss-making Vafseo launch and fading Auryxia sales, the finding sharpens whether Akebia's oral anemia drug can become dialysis-care standard before its reimbursement cushion runs out.
Why Akebia Is Back on Investors' Radar
Akebia Therapeutics, Inc. (AKBA) has spent 2026 convincing dialysis providers that its oral anemia drug Vafseo (vadadustat) deserves a bigger share of a market long dominated by injectable erythropoiesis-stimulating agents, or ESAs. That effort produced its biggest data point yet on June 30, 2026, when Akebia and U.S. Renal Care (USRC), a major dialysis provider, said an interim analysis of their jointly run VOICE trial produced what their release termed "overwhelming statistical evidence" of improved safety for Vafseo versus an ESA: the second favorable hospitalization dataset in two months, after a post-hoc win-odds analysis of Akebia's INNO2VATE trials published in May 2026, meaningful for a launch slower than hoped.
Inside Akebia's Kidney-Disease Business Model
Akebia is a fully integrated biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on kidney disease. Vafseo, FDA-approved in March 2024 for anemia due to chronic kidney disease in dialysis patients, became available in the U.S. in January 2025. It is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, the only such therapy approved or in development for this indication, carrying a boxed warning for thrombotic and cardiovascular risk shared with the ESA class it competes against.
Auryxia (ferric citrate), an oral phosphate binder and iron-deficiency anemia treatment marketed since 2014, lost patent exclusivity in March 2025. Per Akebia's 10-K filed February 26, 2026, Teva received tentative FDA approval for a generic Auryxia on January 22, 2026; one authorized generic is already sold, with more entrants expected in 2026.
What the VOICE Interim Analysis Showed for Akebia (AKBA)
VOICE (Vafseo Outcomes In-Center Experience) is a randomized, open-label trial sponsored by USRC's Kidney Research group, testing Vafseo dosed three times weekly against standard-of-care ESA in hemodialysis patients. It enrolled 2,116 patients using a hierarchical composite endpoint of mortality and hospitalization, analyzed by the win-odds method.
Results as of a June 1, 2026 cutoff showed the trial met its stopping criteria, with a win odds of 1.16 (95% CI 1.06-1.28, p=0.0016), establishing non-inferiority and superiority on the endpoint. The improvement came almost entirely from hospitalizations: 1.11 per patient-year on Vafseo versus 1.23 on the ESA, an incidence rate ratio of 0.90 (95% CI 0.824-0.988). Mortality was statistically indistinguishable, at 8.77% versus 8.78% per 100 patient-years. Acting on the monitoring and steering committees' recommendation, the Primary Investigator stopped the trial early; Akebia expects to submit full results to a scientific meeting. That is the substance behind "overwhelming": a robust, hospitalization-driven signal, not a mortality benefit.
Vafseo's Slow-Building Launch and Auryxia's Declining Base
Akebia's Q1 2026 results, reported May 7, 2026, show a company in transition. Vafseo net product revenue grew to $15.8 million, up from $12.0 million a year earlier, while patients treated rose approximately 60% versus Q4 2025: the strongest quarter of new patient starts since launch, with prescribers up about 28% to roughly 1,025. Auryxia net product revenue fell to $36.2 million from $43.8 million a year earlier, and Akebia expects further declines through 2026 as generic competition expands.
Akebia's Revenue, Profitability, Cash and Debt Position
Total revenue for Q1 2026 was $53.5 million, down from $57.3 million, as Auryxia's decline outpaced Vafseo's growth. Cost of goods sold nearly doubled to $12.3 million on inventory write-downs, and R&D and SG&A rose to $14.8 million and $30.4 million on higher clinical activity and headcount. Net loss was $9.1 million, or $0.03 per share, reversing a $6.1 million net income a year earlier. Cash stood at $162.6 million as of March 31, 2026, down from $184.8 million at year-end 2025; management expects existing cash to fund its plan for at least two years. The 10-Q shows term loans of $48.9 million under a BlackRock credit facility, plus a 2024 CSL Vifor termination agreement requiring decreasing tiered royalties on Vafseo sales up to $450 million, and a $23.4 million working capital fund liability.
Growth Opportunities and the Milestones Ahead
Akebia's opportunity is closing the gap between Vafseo's roughly $1 billion U.S. addressable market and its still-modest quarterly revenue. By year-end 2025, close to 1,000 prescribers across 24 dialysis organizations had prescribed Vafseo, with access operationalized for about 290,000 patients; expanding those protocols is management's key growth lever. Akebia expects topline VOCAL data, a thrice-weekly dosing study within DaVita clinics, in Q4 2026, full VOICE results in early 2027, and initial AKB-9090 and AKB-097 data in 2027.
Material Risks Specific to Akebia
The most immediate risk is timing: Vafseo's TDAPA, in place since January 1, 2025, runs two years and expires around the start of 2027, folding its cost into the standard bundled dialysis rate. Auryxia's patent cliff is underway, with further generics a downside risk to a revenue line management expects to keep shrinking through 2026. Vafseo carries a boxed warning for thrombotic and cardiovascular risk, and excludes non-dialysis CKD patients after Akebia dropped the planned VALOR trial in October 2025 on FDA feedback requiring a much larger study. Akebia also depends on a concentrated set of large dialysis organizations and carries layered obligations (term debt, CSL Vifor royalties and a working capital fund liability) reducing available cash if execution disappoints.
Outlook
In an upside scenario, replicated hospitalization data plus the pending VOCAL and full VOICE readouts could give dialysis organizations stronger rationale to expand Vafseo protocols, accelerating patient growth beyond the 60% pace already reported. In a base case, Vafseo continues its gradual build while Auryxia revenue keeps eroding as guided, leaving overall revenue roughly flat to declining through the TDAPA transition. In a downside scenario, faster generic competition, slower protocol adoption, or an unfavorable outcome once TDAPA expires could pressure revenue and the cash runway cited by management. This is not a price forecast; it describes dynamics likely to unfold over coming quarters.
Conclusion
Akebia Therapeutics (AKBA) sits at an inflection point where clinical validation of Vafseo is arriving faster than commercial scale. The VOICE trial's early stop and hospitalization benefit, replicated from the INNO2VATE win-odds analysis, give Akebia real evidence for dialysis organizations still deciding how broadly to protocolize the drug. But Q1 2026 numbers (a swing to net loss, a shrinking Auryxia base, and a Vafseo franchise generating $15.8 million against roughly $46 million of operating expense) show how much execution stands between that data and durable profitability.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...